NTLA Stock Risk & Deep Value Analysis

Intellia Therapeutics, Inc.

DVR Score

8.8

out of 10

Hidden Gem

The Bottom Line on NTLA

We analyzed Intellia Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran NTLA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 24, 2025•Run Fresh Analysis →

📈NTLA Performance Overview3yr weekly

📊

Unlock NTLA Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

NTLA Deep Value Analysis

Intellia leverages a leading CRISPR gene-editing platform with groundbreaking *in vivo* clinical validation for ATTR, targeting vast underserved markets with curative potential. A strong IP moat, strategic partnerships, and substantial cash runway underpin its ambitious vision. Upcoming pivotal trial results and regulatory filings for lead assets are significant catalysts. While inherent biotech risks exist, the company demonstrates strong execution, a clear path to market leadership, and no fundamental 'dud' characteristics, making it a high-conviction, high-risk growth opportunity.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on NTLA

Create a free account to set price alerts and get notified on Telegram when NTLA hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Intellia Therapeutics, Inc. (NTLA)?

As of September 24, 2025, Intellia Therapeutics, Inc. has a DVR Score of 8.8 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the NTLA DVR analysis updated?

Our AI-powered analysis of Intellia Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 24, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.